Pubblicazioni

CyBorD-DARA in Newly Diagnosed Transplant-Eligible Multiple Myeloma: Results from the 16-BCNI-001/CTRIAL-IE 16-02 Study Show High Rates of MRD Negativity at End of Treatment

2022 - CLINICAL LYMPHOMA MYELOMA & LEUKEMIA

Swan, D; Henderson, R; Mcellistrim, C; Naicker, S D; Quinn, J; Cahill, M R; Mykytiv, V; Lenihan, E; Mulvaney, E; Nolan, M; Parker, I; Natoni, A; Lynch, K; Ryan, A E; Szegezdi, E; Krawczyk, J; Murphy, P; O'Dwyer, M